**Supplementary Table S3. Baseline characteristics of patients with AFP <20 ng/ml vs AFP ≥20 ng/ml.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **AFP <20 ng/ml  (n = 119)** | **AFP ≥20 ng/ml**  **(n = 164)** | ***p* value** |
| Median age (IQR), years | 67.0 (60.0–73.0) | 62.0 (54.8–70.0) | 0.006 | |
| Sex, n (%) |  |  |  | |
| Female | 20 (16.8) | 30 (18.3) | 0.868 | |
| Male | 99 (83.2) | 134 (81.7) |  | |
| Race, n (%) |  |  |  | |
| Asian | 59 (49.6) | 101(61.6) | 0.072 | |
| White | 53 (44.5) | 49 (29.9) |  | |
| Other | 1 (0.8) | 4 (2.4) |  | |
| Unknown | 6 (5.0) | 10 (6.1) |  | |
| Median baseline AFP (IQR), ng/ml | 4.9 (3.0–8.0) | 1381.5  (141.1–9133.0) | <0.001 | |
| ECOG PS, n (%) |  |  |  | |
| 0 | 78 (65.5) | 104 (63.4) | 0.807 | |
| 1 | 41 (34.5) | 60 (36.6) |  | |
| Child-Pugh class, n (%) |  |  |  | |
| A5 | 90 (75.6) | 115 (70.1) | 0.179 | |
| A6 | 27 (22.7) | 48 (29.3) |  | |
| B7 | 0 (0.0) | 1 (0.6) |  | |
| Unknown | 2 (1.7) | 0 |  | |
| Etiology, n (%) |  |  |  | |
| Hepatitis B virus | 49 (41.2) | 89 (54.3) | 0.022 | |
| Hepatitis C virus | 23 (19.3) | 35 (21.3) |  | |
| Non-viral | 47 (39.5) | 40 (24.4) |  | |
| BCLC stage, n (%) |  |  |  | |
| A1/A4 | 3 (2.5) | 5 (3.0) | 0.045 | |
| B | 26 (21.8) | 18 (11.0) |  | |
| C | 90 (75.6) | 141 (86.0) |  | |
| Extrahepatic spread, n (%) | 67 (56.3) | 111 (67.7) | 0.067 | |
| Median time from initial diagnosis (IQR), mo | 12.6 (5.0–32.2) | 4.5 (1.7–14.0) | <0.001 | |
| Prior locoregional therapy,a  n (%) | 100 (84.0) | 102 (62.2) | <0.001 | |
| Median number of metastatic sites (IQR), n | 0.0 (0.0–1.0) | 1.0 (0.0–1.0) | 0.079 | |
| AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; IQR, interquartile range. a Includes local therapy, radiotherapy, and surgery. | | | | |